MedPath

Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis

Phase 4
Terminated
Conditions
Ulcerative Colitis
Interventions
Drug: Placebo
Registration Number
NCT02579733
Lead Sponsor
Kyungpook National University Hospital
Brief Summary

The aim of this study is to determine whether azathioprine is effective for mucosal healing in UC patients who achieved clinical remission by the first course of corticosteroids but not mucosal healing in endoscopy.

Detailed Description

The sample size was calculated based on the previous study showing the difference of mucosal healing rate between azathioprine (58%) and 5-aminosalicylate (21%). With a two-tailed test of α = 0.05 and 1 - ß = 0.8, 52 patients were required.

The placebo drug which is identical to azathioprine will be provided by Celltrion drug company.

Differences in the categorical variables between the groups are examined with χ2 or the Fisher exact test. For comparisons of continuous variables, a Student t test is used.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
16
Inclusion Criteria
  • Ulcerative colitis patients with moderate to severe activity who achieved a clinical remission by the first course of corticosteroids
  • Newly diagnosed or without steroid use during last 1 year
  • Endoscopic Mayo subscore >0
Exclusion Criteria
  • Patients with azathioprine or biologics therapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sugar pillPlaceboPlacebo drug identical to azathioprine (1.5mg/kg) po for 1 year
AzathioprineAzathioprineAzathioprine (1.5mg/kg) po for 1 year
Primary Outcome Measures
NameTimeMethod
Mucosal healing statusone year

Mucosal healing status will be assessed by sigmoidoscopy using Mayo endoscopic score.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Kyungpook National University Hospital

🇰🇷

Daegu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath